Niche market.Abraxane, the first proprietary drug by American American, river, 30 mi (48 km) long, rising in N central Calif. in the Sierra Nevada and flowing SW into the Sacramento River at Sacramento. The discovery of gold at Sutter's Mill (see Sutter, John Augustus) along the river in 1848 led to the California gold rush of Pharmaceutical Partners Inc., seems likely to capture the market for treating breast cancer patients who have failed prior rounds of chemotherapy chemotherapy (kē'mōthĕr`əpē), treatment of disease with chemicals or drugs. One chemotherapeutic approach is the development of selectively toxic substances, i.e. . The Schaumburg, Ill., genetic drug manufacturer, controlled by Los Angeles-based Dr. Patrick Soon-Shiong, released clinical trial data recently showing that the drug did not increase the survival rates of women who had never been treated with chemotherapy. However, the same trial showed a 29 percent reduction in deaths for women who failed a prior Taxol taxol Organic compound with a complex multi-ring molecule that occurs in the bark of Pacific yew trees (Taxus brevifolia). It is active against certain cancers of the lung, ovary, breast, head, and neck, disrupting cell division and interfering with separation of the nuclear regimen regimen /reg·i·men/ (rej´i-men) a strictly regulated scheme of diet, exercise, or other activity designed to achieve certain ends. reg·i·men n. 1. . Abraxane is composed of the same anti-cancer agent as Taxol, but formulated for·mu·late tr.v. for·mu·lat·ed, for·mu·lat·ing, for·mu·lates 1. a. To state as or reduce to a formula. b. To express in systematic terms or concepts. c. in such a way that more powerful doses can be administered. News that the drug is likely a niche player sent shares down nearly 4 percent to just above $50 since the Feb. 25 announcement. Still, that's above the $32.66 close on Jan. 5, when Wall Street bears were betting the Food and Drug Administration wouldn't even approve the drug for sale, which it did two days later. Staff reporter Laurence Darmiento can be reached at (323) 549-5225, ext. 237, or at ldarmiento@labusinessjournal.com. |
|
||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion